S
Seth M. Cohen
Researcher at University of California, San Diego
Publications - 511
Citations - 39017
Seth M. Cohen is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Neutrino & Medicine. The author has an hindex of 91, co-authored 476 publications receiving 33642 citations. Previous affiliations of Seth M. Cohen include Massachusetts Institute of Technology & École Polytechnique Fédérale de Lausanne.
Papers
More filters
Journal ArticleDOI
Self-assembly of heteroleptic [Cu(dipyrrinato)(hfacac)] complexes directed by fluorine-fluorine interactions.
Sara R. Halper,Seth M. Cohen +1 more
TL;DR: The results presented here demonstrate that fluorine-fluorine contacts can be used to modulate supramolecular structures in the solid state.
Journal ArticleDOI
A bioinorganic perspective on matrix metalloproteinase inhibition.
David T. Puerta,Seth M. Cohen +1 more
TL;DR: It is suggested that significant efforts to augment ZBGs combined with the available information on inhibitor backbone design will accelerate the discovery of improved MPIs and newly devised drug design methods will help to realize this proposal.
Journal ArticleDOI
Self-Assembly of Metal-Organic Framework (MOF) Nanoparticle Monolayers and Free-Standing Multilayers.
TL;DR: Self-assembled MOF monolayers (SAMMs) were assembled at a liquid-air interface to produce films that are 87 wt% (89 vol%) MOF and retain the crystallinity and porosity of the MOF particles.
Journal ArticleDOI
Chelator fragment libraries for targeting metalloproteinases
Arpita Agrawal,Sherida L. Johnson,Jennifer A. Jacobsen,Melissa T. Miller,Li-Hsing Chen,Maurizio Pellecchia,Seth M. Cohen +6 more
TL;DR: The findings clearly demonstrate that chelators can be used to generate libraries suitable for fragment-based lead design (FBLD) directed at important metalloproteins.
Journal Article
Chronicity of depressive episode in relation to antidepressant-placebo response.
TL;DR: The response to placebo was low in subjects who were depressed for 1 year or longer as compared to a higher response rate among those who were not as chronically depressed, and the response to imipramine and adinazolam was not related to the duration of presenting depressive episode.